GIMEMA

Ongoing clinical trials and future developments of the hematological no profit research
M. Vignetti
SYMPOSIUM

Bispecific antibodies in lymphomas and myeloma
F. Patriarca
Bispecific antibodies in lymphomas and myeloma
P.L. Zinzani
SESSION I

CAR-T

Allogeneic CAR-T cells in BCP-ALL
F. Del Bufalo
CAR-T cells in T-ALL
F. Locatelli
CAR-T cells in multiple myeloma
M. Cavo
New indications of CAR-T cells in NHL lymphoma
P. Corradini
Pre-clinical development of CD123-targeting NK cells
C. Quintarelli
CAR-CIK cells for patients with MRD relapsed disease
A. Rambaldi
SESSION II

MYELOPROLIFERATIVE NEOPLASMS

Interpreting the new classifications (WHO, ICC) for myeloproliferative neoplasms
U. Gianelli
The significance of molecular response in MPN
P. Guglielmelli
Novel concepts for thrombosis risk stratification in PV
V. De Stefano
Combination therapies in myelofibrosis
F. Passamonti
SESSION III

MYELODISPLASTIC SYNDROME

MDS and autoimmune diseases
B. Fattizzo
Management of MDS with T-LGL
R. Zambello
Novel approaches to therapy of anemia in MDS
R. Latagliata
Novel approaches to therapy of thrombocytopenia in MDS
E.N. Oliva
SESSION IV

ACUTE MYELOID LEUKEMIA

The novel genomic classifications (ELN and ICC) of acute myeloid leukemia in adults: what is changing?
F. Guolo
Selecting therapy for acute myeloid leukemia with or without predictive biomarkers or therapeutically actionable genomic or molecular alterations
A. Candoni
Measurable residual disease in acute myeloid leukemia. Technical and prognostic issues and the role of post consolidation therapy
F. Buccisano
Novel adaptive immune therapies and innate immune modifier drug to target acute myeloid leukemia
A. Curti
SESSION V

ACUTE LYMPHOBLASTIC LEUKEMIA

Prophylaxis and treatment of leukemia relapse after allogeneic stem cell transplantation
F. Lussana
Translational research within clinical trials of the GIMEMA study group
S. Chiaretti
When viruses meet fungi: tackling the enemies in ALL before and after transplantation
A. Busca
SESSION VI

CHRONIC LYMPHOCYTIC LEUKEMIA

MRD detection in chronic lymphocytic leukemia: flow cytometry and PCR
S. Galimberti
Genomic complexity as a prognostic/predictive factor
G.M. Rigolin
Drivers of therapeutic decision in patients with and without TP53 aberrations
A. Visentin
Treatment options in relapsed/refractory CLL after covalent BTI inhibitors and venetoclax
L. Scarfò
SESSION VII

GVHD: WHERE DO WE STAND?

Perspectives and limits of post-transplant cyclophosphamide
S. Sica
Perspectives and limits of ATG/ATLG
F. Bonifazi
Perspectives and limits of ex vivo T-cell depletion in children
M. Algeri
Privacy Policy | Cookie Policy